Edition:
United States

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

63.83EUR
8:04am EDT
Change (% chg)

€1.34 (+2.14%)
Prev Close
€62.49
Open
€62.70
Day's High
€63.90
Day's Low
€62.59
Volume
14,860
Avg. Vol
38,194
52-wk High
€82.83
52-wk Low
€38.69

DBV.PA

Chart for DBV.PA

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.76
Market Cap(Mil.): €1,506.24
Shares Outstanding(Mil.): 24.10
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 36.15 37.05
EPS (TTM): -2.03 -- --
ROI: -19.98 15.11 14.35
ROE: -20.42 16.17 15.56

BRIEF-Dbv Technologies appoints Lucia Septién as chief medical officer

* Announced appointment of Lucia Septién, M.D., as chief medical officer Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 05 2016

BRIEF-DBV Technologies completes recruitment global phase III study of viaskin peanut

* Announces on Monday the completion of recruitment in global phase III study of viaskin peanut for the treatment of peanut allergic children

Jun 28 2016

BRIEF-DBV Technologies publishes preclinical data in JACI about EPIT

* DBV Technologies announces publication of preclinical data in JACI suggesting EPIT provides sustained protection against anaphylaxis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 13 2016

UPDATE 2-Nestle, on health kick, moves into milk allergy testing

* DBV Technologies shares gain 5 percent (Adds Nestle executive comment, more on Nestle products)

May 31 2016

BRIEF-DBV Technologies and Nestlé Health Science to collaborate on pediatric milk allergy test

* DBV Technologies and Nestlé Health Science form collaboration to develop and commercialize a novel diagnostic test for pediatric milk allergy

May 31 2016

BRIEF-DBV Technologies cash and cash equivalents at EUR 308.6 MLN as of March 31, 2016

* DBV'S cash and cash equivalents amounted to 308.6 million euros ($351.56 million) as of March 31, 2016, compared to 323.4 million euros as of December 31, 2015 Source text for Eikon: Further company coverage: ($1 = 0.8778 euros) (Gdynia Newsroom)

Apr 29 2016

BRIEF-DBV Technologies FY net loss widens to 44.7 million euros

* FY total income 6.2 million euros vs 4.8 million euros ($5.48 million) year ago

Apr 07 2016

BRIEF-DBV Technologies presents additional phase IIb results with Viaskin Peanut

* Announced on Sunday additional phase IIb trial results with Viaskin peanut presented at the 2016 AAAAI meeting continue to support treatment safety, efficacy and compliance

Mar 07 2016

BRIEF-DBV Technologies presents update on NIAID-sponsored CoFAR6 phase II trial

* Announced on Friday the presentation from NIAID-sponsored CoFAR6 phase II trial reaffirming Viaskin peanut safety and efficacy

Mar 07 2016

BRIEF-DBV Technologies announces publication of phase Ib trial results of Viaskin Peanut

* Announced the publication of results from a Phase Ib trial showing that Viaskin Peanut was observed to have a favorable safety and tolerability profile

Feb 26 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Pechala's Reports
$25.00
Provider : Wright Reports
$75.00
Provider : Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.